Prognostic role of the stromal cell derived factor-1 in patients with hepatitis B virus-related acute-on-chronic liver failure

Table 1 Clinical and biochemical characteristics of all participants

	HBV-related ACLF (n = 30)	CHB (n = 27)	Healthy controls (n = 20)	P value
Age (yr)	42 ± 14	41 ± 15	39 ± 14	0.641
Gender (male/female)	25/5	17/10	13/7	0.179
Albumin (g/L)	29.7 ± 4.5	40.1 ± 6.0	44.4 ± 4.3	< 0.001
ALT (U/L)	400.9 ± 318.8	189.7 ± 121.2	21.1 ± 10.2	< 0.001
AST (U/L)	362.2 ± 249.1	147.3 ± 87.0	20.6 ± 6.9	< 0.001
TBIL (µmol/L)	381.6 ± 178.1	41.5 ± 38.8	12.0 ± 3.6	< 0.001
DBIL (µmol/L)	216.4 ± 111.3	19.7 ± 23.8	3.7 ± 1.2	< 0.001
INR	2.6 ± 0.9	1.1 ± 0.1	-	< 0.001
PTA (%)	35.2 ± 12.1	98.1 ± 16.1	-	< 0.001
HBVDNA (log10 copies/mL)	4.7 ± 1.6	5.5 ± 1.6	-	0.084
HBeAg (+)/HBeAg (-)	11/19	15/12	-	0.153
30-d mortality	19 (63.3%)	0 (0)	0 (0)	-

Values are given as mean ± SD. HBV: Hepatitis B virus; ACLF: Acute-on-chronic liver failure; CHB: Chronic hepatitis B; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; DBIL: Direct bilirubin; INR: International normalized ratio; PTA: Prothrombin activity; HBeAg: Hepatitis B e antigen.